Let me begin by saying cheers to how the market has performed over the past few months. With all the tasty money I have made with this exuberant 2024 rally, it is only right I use some of the proceeds to throw into what some might call a “LOTTO”, I call a diamond in the rough. May I present to you NervGen : (NGENF). NervGen is a clinical stage biotech company that is trying to redefine what was Once thought impossible; regeneration of the central nervous system. Jerry Silver has quarterbacked the research for a central nervous system regeneration cure for almost 30 years. NervGen is trying to enable those that cannot feel their legs be able to take their first steps. “This is not revolutionary, it’s biblical.” NervGen has been given fast track designation which is intended to facilitate development and expedite review of drugs to treat serious or life-threatening conditions so that a product can reach the market expeditiously. Features of this designation include opportunities for frequent interactions with the review team. These include meetings with the FDA to discuss items such as study design, extent of safety data required to support approval, dose-response concerns, accelerated approval, the structure and content of an NDA, and other critical issues. In addition, such a product could be eligible for priority review if supported by clinical data at the time of NDA.
Now let’s dive into the bread and butter of the company which is their leading drug NVG-29; because let’s be real most of their other drugs are dog shit otherwise they wouldn’t be a penny stock.
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular wedge domain of the receptor type protein tyrosine phosphatase sigma (PTPσ). NVG-291-R, a rodent analog of NVG-291, has been shown to promote nervous system repair and functional recovery in animal models of spinal cord injury (acute and chronic intervention), peripheral nerve injury, multiple sclerosis and stroke, through enhanced plasticity, axonal regeneration, and remyelination. NervGen has initiated a Phase 1b/2a placebo-controlled proof-of-concept trial (NCT05965700) to evaluate the efficacy of NVG-291 in two separate cohorts of individuals with cervical spinal cord injury: chronic (1-10 years post-injury) and subacute (10-49 days post-injury), given demonstrated efficacy in preclinical models of both chronic and acute spinal cord injury. Initial results are expected in mid-2024.
Now that we have identified the diamond in the rough. Lets talk stonks, at some point in 2023 ( fuck off my memory is bad and im to lazy to find this) a researcher and scientist working on testing the drug with rodents revealed on an interview that it worked wonders with the rodents. Following this comment the stock saw a 30% increase in value shortly after. That rally fizzled out because without FDA approval your drug company isn’t shit. With results of trials coming up in 2024 and a small insight to the effectiveness of the drug on animals gives me slight confidence of approval (Gut feeling). With that approval the share price will proceed to sky rocket into the high double digits with a rally ensuing before approval. I am predicting a run up to 3-4.5 dollars pre trial and a jump to 10+ if the results are positive in 2024. Now this play comes with serious risks as clinical stage biotech companies operate on cash runways and if they fail the trials then they become virtually worthless to shareholders. If this drug does not make it past clinical trials then you can kiss your money away.